Free Trial
NYSEAMERICAN:VNRX

VolitionRx (VNRX) Stock Price, News & Analysis

VolitionRx logo
$0.49 +0.01 (+1.49%)
As of 05/28/2025 04:10 PM Eastern

About VolitionRx Stock (NYSEAMERICAN:VNRX)

Key Stats

Today's Range
$0.48
$0.51
50-Day Range
$0.42
$0.57
52-Week Range
$0.40
$0.90
Volume
70,780 shs
Average Volume
181,013 shs
Market Capitalization
$31.07 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada.

Receive VNRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for VolitionRx and its competitors with MarketBeat's FREE daily newsletter.

VNRX Stock News Headlines

Elon just did WHAT!?
As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they gotten away with it, the Fed and U.S. banks could have seized control of our financial lives forever. But Trump stopped them cold on January 23rd, 2025, when he outlawed CBDCs… Paving the way for Elon Musk's secret master plan.
VolitionRX Q1 2025 Earnings Preview
See More Headlines

VNRX Stock Analysis - Frequently Asked Questions

VolitionRx's stock was trading at $0.58 at the beginning of the year. Since then, VNRX shares have decreased by 15.2% and is now trading at $0.4917.
View the best growth stocks for 2025 here
.

VolitionRx Limited (NYSEAMERICAN:VNRX) released its quarterly earnings data on Wednesday, November, 10th. The medical research company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.11) by $0.02. The medical research company earned $0.03 million during the quarter, compared to analyst estimates of $0.03 million. VolitionRx had a negative net margin of 9,158.31% and a negative trailing twelve-month return on equity of 15,493.47%.

Shares of VNRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that VolitionRx investors own include Chesapeake Energy (CHKAQ), Bausch Health Companies (BHC), Avino Silver & Gold Mines (ASM), Avino Silver & Gold Mines (ASM), Exelixis (EXEL), T2 Biosystems (TTOO) and Gilead Sciences (GILD).

Company Calendar

Last Earnings
11/10/2021
Today
5/28/2025
Next Earnings (Estimated)
8/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSEAMERICAN
Sector
Medical
Industry
Diagnostics & Research
Sub-Industry
Pharmaceutical Products
Current Symbol
NYSEAMERICAN:VNRX
Previous Symbol
NYSEMKT:VNRX
Employees
80
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$30.27 million
Net Margins
-9,158.31%
Pretax Margin
-9,257.43%
Return on Equity
-15,493.47%

Debt

Sales & Book Value

Annual Sales
$310,000.00
Price / Cash Flow
N/A
Book Value
($0.05) per share
Price / Book
-9.83

Miscellaneous

Free Float
53,450,000
Market Cap
$31.07 million
Optionable
Not Optionable
Beta
1.59
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

This page (NYSEAMERICAN:VNRX) was last updated on 5/29/2025 by MarketBeat.com Staff
From Our Partners